Industries / Health / Healthcare / Weight-loss clinics
Rules and advertising
This work sets and enforces limits on what weight-loss sellers may claim, on whether prescription weight-loss medicines may be advertised to the public, and on who may sell them at all.
7
Milestones achieved, from 1965 to 2025.
1
To watch for: announced, not yet confirmed outside.
2
Open deliverables. Nobody has shipped them.
The road
AchievedWatch forOpen
Achieved
1965
Germany limits drug ads
Germany's law on advertising in health care, the Heilmittelwerbegesetz (HWG) of 11 July 1965, in its current section 10, allows prescription-only medicines to be advertised only to doctors, dentists, vets, pharmacists and those who lawfully trade in such medicines. A German weight-loss service therefore may not advertise a prescription drug to the public.
Credit
the German federal legislature
2020
UK warns weight-loss advertisers
In the UK, regulation 284 of the Human Medicines Regulations 2012 bans any ad "likely to lead to the use of a prescription-only medicine", and rule 12.12 of the advertising code says such medicines may not be advertised to the public. After many complaints about ads for prescription weight-loss treatments in 2020, the Committee of Advertising Practice (CAP), which writes the code, issued an enforcement notice to the advertisers of these medicines; it was updated in September 2025.
Credit
CAP and the Advertising Standards Authority (ASA), which enforces the code
2023
Thousands of ads, counted
In June 2023 NBC News searched Meta's public Ad Library over several days and found more than 4,000 active US ad campaigns on Facebook and Instagram mentioning semaglutide, against 800 on Instagram and 930 on Facebook for Viagra. After NBC sent Meta questions, the count fell to about 560, 88% lower than the day before; Meta attributed the drop to its enforcement and said it requires advertisers of prescription drugs to get written permission and show an appropriate license.
LessonA public ad library lets outsiders measure what a platform's checks let through.
Credit
NBC News
2024
Australia fines telehealth ads
Australian law bans advertising prescription-only medicines to consumers, and the TGA made weight-loss medicines a compliance priority for 2023 to 2025. Between January and August 2024 it issued more than 70 infringement notices to 19 entities, about A$1 million in fines, for unlawful advertising of prescription-only medicines, including notices to online telehealth clinics, according to the law firm Maddocks. In September 2025 the telehealth operator Midnight Health paid 10 notices totaling A$198,000 for advertising prescription weight-loss medicines between June 2024 and January 2025.
Credit
TGA
2025
Pens and jabs count too
On 9 July 2025 the ASA published nine rulings on ads that never named a drug but still promoted prescription weight-loss medicines: words such as "weight loss injections", "weight loss pen" and "obesity treatment jab", images of unbranded injection pens or vials, and ads for a "consultation" that linked to pages offering only injections. On 23 September 2025 the ASA, the Medicines and Healthcare products Regulatory Agency (MHRA) and the GPhC issued an updated joint enforcement notice that lists these signals.
LessonBanning the drug's name alone did not stop ads for the drug.
Credit
ASA; MHRA; GPhC
2025
A clinic's hidden fees
NextMed, a US telehealth company whose members got prescriptions for GLP-1 drugs such as Wegovy, advertised monthly fees of $138 to $188 that, the Federal Trade Commission (FTC) alleged, did not include the drug, the required consultations or lab work. The FTC also alleged that it claimed members lost 53 pounds and 23% of body weight on average with no records to back the claim, used fake reviews and testimonials, and failed to disclose a one-year term and an early termination fee. The FTC proposed a consent order in July 2025 and approved it as final, 2 to 0, on 3 December 2025: NextMed and its two founders must pay $150,000, disclose cancellation and refund terms before payment and offer a simple way to cancel.
LessonA claim of average weight loss needs records behind it.
Credit
FTC, Division of Advertising Practices
2025
An illegal pen factory raided
On 24 October 2025 the MHRA's Criminal Enforcement Unit said it had dismantled an illegal factory in a Northampton warehouse that made and shipped unlicensed weight-loss pens, the first found in the UK. Officers seized tens of thousands of empty pens and more than 2,000 unlicensed retatrutide and tirzepatide pens awaiting dispatch to customers, which the MHRA believes is the largest single seizure of trafficked weight-loss medicines recorded by any law enforcement agency.
Credit
MHRA Criminal Enforcement Unit; Northamptonshire Police
Watch for
Compliance claimed at 99%
On 2 April 2026 the ASA said its AI-based Active Ad Monitoring system had captured and assessed tens of thousands of weight-loss ads from high-priority advertisers and found about 900 ads likely to break the rules, from 38 of the 44 advertisers it monitored. After targeted action, it said, compliance with the enforcement notice "now stands at around 99%" among monitored paid-for ads. The figure is the regulator's own measure of its own enforcement and covers only the advertisers it chose to watch.
Achieved whenan outside count of weight-loss ads in public ad libraries, across all UK advertisers, finds a similar rate.
Claimed by
ASA, April 2026
Open
01
Outside count of banned ads
A monthly public count of paid ads that promote prescription weight-loss medicines to the public in the UK, Ireland, Germany, France and Australia, where that is against the law. Ads are collected from the Meta Ad Library by keyword in each language and from the Google Ads Transparency Center by known advertiser, then classified against the signals the ASA lists in its rulings (a named drug, "jab" or "pen", pictures of pens or vials, a linked page offering only injections), with a person checking a random sample. Each advertiser is also looked up in the national pharmacy register, and results are broken down by country and advertiser.
The briefCredit · unclaimed02
Pages after a warning letter
A public before-and-after check of every FDA warning letter sent since September 2025 to a telehealth company or clinic over claims about compounded GLP-1 drugs. For each letter, list the claims it quotes, find dated copies of each cited web page from before the letter and from 30, 90 and 180 days after, and record whether each claim was removed, reworded or left in place, and whether the site still sells the product.
The briefCredit · unclaimed
Open 01 · the brief
Outside count of banned ads
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
A monthly public count of paid ads that promote prescription weight-loss medicines to the public in the UK, Ireland, Germany, France and Australia, where that is against the law. Ads are collected from the Meta Ad Library by keyword in each language and from the Google Ads Transparency Center by known advertiser, then classified against the signals the ASA lists in its rulings (a named drug, "jab" or "pen", pictures of pens or vials, a linked page offering only injections), with a person checking a random sample. Each advertiser is also looked up in the national pharmacy register, and results are broken down by country and advertiser.
Why it is still open
The UK's figure of about 99% compliance comes from the ASA's own system watching 44 advertisers, and the ASA publishes no ad-level data. LegitScript, a private company whose certification Google requires of telemedicine advertisers, said in July 2024 that it had monitored more than 500,000 paid search ads mentioning GLP-1 drugs in two months and that 83% of the problem ads ran where prescription-drug ads are not allowed, but it named no countries and published no data. Searches in November 2026 found no published count for Ireland, Germany, France or Australia.
Built with what exists
the Meta Ad Library and the Google Ads Transparency Center, both public; national pharmacy registers such as the GPhC's online register and the Pharmaceutical Society of Ireland's register; a browser agent such as Browser Use 1.0 (see the Note "Deleting 80% to start over") to collect ads; a classifier such as Gemini Decision 1, which returns probabilities for up to 1,000 fixed-answer questions in one request (see the Note "A thousand questions, one pass"), or an open-weight vision-language model for images; the ASA's published rulings as labeled examples.
First step
Search the Meta Ad Library for "Mounjaro" and "weight loss injection" in the UK and Ireland on one day and hand-code the first 100 ads against the ASA's listed signals.
Done looks like
Three consecutive monthly releases; for each country, the number of ads found, the share judged to promote a prescription medicine and the share from advertisers on no pharmacy register, each with a 95% confidence interval from a hand-checked sample of at least 200 ads; the UK share set beside the ASA's 99%; data and code published.
Open 02 · the brief
Pages after a warning letter
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
A public before-and-after check of every FDA warning letter sent since September 2025 to a telehealth company or clinic over claims about compounded GLP-1 drugs. For each letter, list the claims it quotes, find dated copies of each cited web page from before the letter and from 30, 90 and 180 days after, and record whether each claim was removed, reworded or left in place, and whether the site still sells the product.
Why it is still open
The FDA announced 30 warning letters to telehealth companies on 3 March 2026, its second group since September 2025, for claims implying that compounded products are the same as approved ones and for branding that hides who compounds them; another 25 followed in June 2026. The FDA issues a close-out letter only after it has verified a company's corrections, and publishes no count of how many warned pages changed. A search in November 2026 found no follow-up study.
Built with what exists
the FDA's warning letter pages; the Internet Archive's Wayback Machine and its CDX index of dated snapshots, and Common Crawl; Browser Use 1.0 to capture the current pages (see the Note "Deleting 80% to start over"); an AI model such as Claude to compare each quoted claim with the later page text, with a person checking every judgment that a claim was removed.
First step
Copy out the quoted claims in the 30 letters announced on 3 March 2026 and find a dated snapshot of each cited page from before the letter and from 90 days after.
Done looks like
Every such letter from September 2025 to the release date coded, at least 100 letters; for each letter, the share of quoted claims removed at 30, 90 and 180 days; two people agreeing on at least 90% of a checked sample of 200 claims; data and code published.